---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-019196"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2021-08-10T23:59:59+00:00"
generated_at: "2026-06-29T16:07:28.449739+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Interpace Q2 revenue $11.2M (+105% YoY); gross margin 48% vs 29%, adj EBITDA loss narrows to $0.3M

## Summary
- Net revenue $11.2M (+105% vs Q2 2020); six-month revenue $21.0M (+45% YoY).
- Gross profit margin 48% (Q2 2020: 29%); loss from continuing ops improved to $3.4M from $5.5M.
- Adjusted EBITDA $(0.3)M vs $(4.2)M in prior year; cash collections hit $11.5M in Q2, DSO down 32%.
- Cash balance rose to $4.0M at July 31 from $2.8M at Dec 31, 2020; on track for >35% FY revenue growth.
- New PLA code 0245U for ThyGeNEXT at $2,919; eviCore coverage for ThyGeNEXT/ThyraMIR effective July 1.

## SEC filing metadata
- accession: 0001493152-21-019196
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2021-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000149315221019196/0001493152-21-019196-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000149315221019196/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-019196
- JSON: https://secwatch.observer/filing/0001493152-21-019196.json
- Plain text: https://secwatch.observer/filing/0001493152-21-019196.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.